Riluzole PMCS ( DrugBank: Riluzole )


1 disease
IDDisease name (Link within this page)Number of trials
18Spinocerebellar degeneration1

18. Spinocerebellar degeneration


Clinical trials : 76 Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-001481-23-FR
(EUCTR)
12/09/201730/10/2017NAMULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL WITH RILUZOLE IN SPINOCEREBELLAR ATAXIA TYPE 2 - ATRIL SCA2 patients, both gender, at least 18 years of age
MedDRA version: 20.0;Level: PT;Classification code 10057660;Term: Spinocerebellar ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Riluzole PMCS
Product Name: Riluzole PMCS
INN or Proposed INN: Riluzole
Other descriptive name: Riluzole
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
50Phase 3France